Covered recipient · General Payments record
KATHERINE B REED
Allopathic & Osteopathic Physicians Dermatology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2019 · Entire year
$547.33
32 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2019 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $547.33 | 32 |
By paying entity
PY2019 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| AbbVie, Inc. | $140.07 | 8 |
| Lilly USA, LLC | $102.74 | 6 |
| PFIZER INC. | $71.65 | 4 |
| Celgene Corporation | $48.30 | 2 |
| Novartis Pharmaceuticals Corporation | $42.89 | 3 |
| GENZYME CORPORATION | $32.94 | 2 |
| Biofrontera Inc. | $28.74 | 2 |
| Amgen Inc. | $25.33 | 2 |
| Integra LifeSciences Corporation | $25.33 | 1 |
| Helsinn Therapeutics (U.S.), Inc. | $15.78 | 1 |
| PruGen, Inc. Pharmaceuticals | $13.56 | 1 |
Page 1 of 1; records 1–32 of 32 matching records. This page contains 32 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
KATHERINE B REED
NPI 1396919569 · CMS profile ID 335358
Allopathic & Osteopathic Physicians / Dermatology
SPOKANE, WA
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 1 of 1; records 1–32 of 32 matching records. This page contains 32 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1396919569?year=2019&recipient=provider#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- KATHERINE B REED, NPI 1396919569, CMS profile ID 335358. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–32 of 32 matching records. This page contains 32 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1396919569?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- APA 7
- IndustryPayments. (2026). KATHERINE B REED, NPI 1396919569, CMS profile ID 335358. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–32 of 32 matching records. This page contains 32 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1396919569?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- Bluebook
- KATHERINE B REED, NPI 1396919569, CMS profile ID 335358, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–32 of 32 matching records. This page contains 32 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1396919569?year=2019&recipient=provider#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2019
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30
32 matching records · $547.33 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 1–32 of 32.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| GENZYME CORPORATION | $15.07 | 11/06/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 694219337 | CMS |
| Lilly USA, LLC | $17.40 | 11/04/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 657930113 | CMS |
| Novartis Pharmaceuticals Corporation | $13.07 | 10/28/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 659860567 | CMS |
| Biofrontera Inc. | $7.77 | 10/21/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 690544023 | CMS |
| AbbVie, Inc. | $18.97 | 10/16/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 647699319 | CMS |
| Celgene Corporation | $23.94 | 08/28/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 672886457 | CMS |
| Amgen Inc. | $12.12 | 08/22/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 662591459 | CMS |
| Novartis Pharmaceuticals Corporation | $17.57 | 08/21/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 659860565 | CMS |
| Lilly USA, LLC | $15.87 | 08/20/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 657943901 | CMS |
| AbbVie, Inc. | $21.34 | 07/25/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 647699313 | CMS |
| Celgene Corporation | $24.36 | 07/24/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 672886273 | CMS |
| GENZYME CORPORATION | $17.87 | 07/17/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 694098869 | CMS |
| Lilly USA, LLC | $18.12 | 07/10/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 657950651 | CMS |
| PFIZER INC. | $16.46 | 06/25/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 672253685 | CMS |
| AbbVie, Inc. | $17.92 | 06/20/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 647699331 | CMS |
| Integra LifeSciences Corporation | $25.33 | 06/19/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 697158539 | CMS |
| AbbVie, Inc. | $15.52 | 06/10/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 647699327 | CMS |
| AbbVie, Inc. | $17.01 | 05/30/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 647699311 | CMS |
| Novartis Pharmaceuticals Corporation | $12.25 | 05/29/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 659860563 | CMS |
| PruGen, Inc. Pharmaceuticals | $13.56 | 05/22/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 707764987 | CMS |
| PFIZER INC. | $18.45 | 05/21/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 672021947 | CMS |
| Lilly USA, LLC | $14.24 | 05/02/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 657930111 | CMS |
| AbbVie, Inc. | $17.13 | 04/29/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 647699353 | CMS |
| Amgen Inc. | $13.21 | 04/16/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 662591457 | CMS |
| Helsinn Therapeutics (U.S.), Inc. | $15.78 | 04/11/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 655947391 | CMS |
| AbbVie, Inc. | $15.04 | 03/20/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 647699325 | CMS |
| Lilly USA, LLC | $17.20 | 03/12/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 657950649 | CMS |
| PFIZER INC. | $20.09 | 02/27/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 671891609 | CMS |
| Biofrontera Inc. | $20.97 | 02/20/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 667996653 | CMS |
| PFIZER INC. | $16.65 | 02/12/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 671853273 | CMS |
| Lilly USA, LLC | $19.91 | 01/30/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 657926571 | CMS |
| AbbVie, Inc. | $17.14 | 01/22/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 647699321 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $734,267.33 | 246 |
| PY2024 | Principal investigator | $853,745.12 | 356 |
| PY2023 | Principal investigator | $644,757.85 | 253 |
| PY2022 | Principal investigator | $361,336.03 | 142 |
| PY2021 | Principal investigator | $277,998.71 | 117 |
| PY2020 | Principal investigator | $149,365.00 | 24 |
| PY2019 | Principal investigator | $53,682.69 | 24 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2022
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
142 records in PY2022
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Incyte Corporation | $2,068.64 | 12/29/2022 | Non-covered Recipient Entity DERMATOLOGY SPECIALISTS OF SPOKANE | A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Children (Ages 2 Years to 12 Years) With Atopic Dermatitis (TRuE-AD3) | No dispute reported | 06/30/2026 | 905238625 |
| Principal investigator 1 | Incyte Corporation | $10,824.84 | 12/29/2022 | Non-covered Recipient Entity DERMATOLOGY SPECIALISTS OF SPOKANE | A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 Followed by an Extension Period in Participants With Vitiligo | No dispute reported | 06/30/2026 | 905238627 |
| Principal investigator 1 | ABBVIE INC. | $2,252.50 | 12/15/2022 | Non-covered Recipient Entity DERMATOLOGY SPECIALISTS OF SPOKANE | A Study of Oral Upadacitinib Tablet Compared to Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa to Assess Change in Disease Symptoms | No dispute reported | 06/30/2026 | 889825339 |
| Principal investigator 1 | Incyte Corporation | $1,400.00 | 12/09/2022 | Non-covered Recipient Entity DERMATOLOGY SPECIALISTS OF SPOKANE | Topical Ruxolitinib Evaluation in Vitiligo Study 1 (TRuE-V1)A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Extension Period in Participants With Vitiligo | No dispute reported | 06/30/2026 | 905238629 |
| Principal investigator 1 | ABBVIE INC. | $2,591.00 | 12/08/2022 | Non-covered Recipient Entity DERMATOLOGY SPECIALISTS OF SPOKANE | A Study to Assess Adverse Events and Disease Activity With Cedirogant (ABBV-157) in Adult Participants With Moderate to Severe Psoriasis | No dispute reported | 06/30/2026 | 889823929 |
| Principal investigator 1 | ARENA PHARMACEUTICALS, INC. | $6,743.75 | 12/05/2022 | Non-covered Recipient Entity DERMATOLOGY SPECIALISTS OF SPOKANE | A MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 24WEEK STUDY WITH A 28WEEK OPENLABEL EXTENSION TO ASSESS THE SAFETY AND EFFICACY OF ETRASIMOD IN SUBJECTS WITH MODERATETOSEVERE ALOPECIA AREATA | No dispute reported | 06/30/2026 | 949763425 |
| Principal investigator 1 | ARENA PHARMACEUTICALS, INC. | $1,901.88 | 12/05/2022 | Non-covered Recipient Entity DERMATOLOGY SPECIALISTS OF SPOKANE | A MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 24WEEK STUDY WITH A 28WEEK OPENLABEL EXTENSION TO ASSESS THE SAFETY AND EFFICACY OF ETRASIMOD IN SUBJECTS WITH MODERATETOSEVERE ALOPECIA AREATA | No dispute reported | 06/30/2026 | 949763427 |
| Principal investigator 1 | Horizon Therapeutics plc | $16,749.00 | 12/05/2022 | Non-covered Recipient Entity DERMATOLOGY SPECIALISTS OF SPOKANE PLLC | A PHASE 2A, OPEN LABEL, PROOF OF CONCEPT TRIAL OF DAXDILIMAB FOR THE TREATMENT OF MODERATE TO SEVERE ALOPECIA AREATA | No dispute reported | 06/30/2026 | 937594439 |
| Principal investigator 1 | Incyte Corporation | $5,493.42 | 12/01/2022 | Non-covered Recipient Entity DERMATOLOGY SPECIALISTS OF SPOKANE | A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Children (Ages 2 Years to 12 Years) With Atopic Dermatitis (TRuE-AD3) | No dispute reported | 06/30/2026 | 905238623 |
| Principal investigator 1 | ABBVIE INC. | $50.00 | 11/23/2022 | Non-covered Recipient Entity DERMATOLOGY SPECIALISTS OF SPOKANE | A Study to Assess Adverse Events and Disease Activity With Cedirogant (ABBV-157) in Adult Participants With Moderate to Severe Psoriasis | No dispute reported | 06/30/2026 | 889821815 |
| Principal investigator 1 | ABBVIE INC. | $1,702.00 | 11/22/2022 | Non-covered Recipient Entity DERMATOLOGY SPECIALISTS OF SPOKANE | A Study to Assess Adverse Events and Disease Activity With Cedirogant (ABBV-157) in Adult Participants With Moderate to Severe Psoriasis | No dispute reported | 06/30/2026 | 889821671 |
| Principal investigator 1 | ABBVIE INC. | $471.00 | 11/11/2022 | Non-covered Recipient Entity DERMATOLOGY SPECIALISTS OF SPOKANE | A Study of Oral Upadacitinib Tablet Compared to Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa to Assess Change in Disease Symptoms | No dispute reported | 06/30/2026 | 889820711 |
| Principal investigator 1 | Incyte Corporation | $232.85 | 11/10/2022 | Non-covered Recipient Entity DERMATOLOGY SPECIALISTS OF SPOKANE | A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Children (Ages 2 Years to 12 Years) With Atopic Dermatitis (TRuE-AD3) | No dispute reported | 06/30/2026 | 905238617 |
| Principal investigator 1 | ARENA PHARMACEUTICALS, INC. | $60.94 | 11/07/2022 | Non-covered Recipient Entity DERMATOLOGY SPECIALISTS OF SPOKANE | A MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 24WEEK STUDY WITH A 28WEEK OPENLABEL EXTENSION TO ASSESS THE SAFETY AND EFFICACY OF ETRASIMOD IN SUBJECTS WITH MODERATETOSEVERE ALOPECIA AREATA | No dispute reported | 06/30/2026 | 949763277 |
| Principal investigator 1 | ARENA PHARMACEUTICALS, INC. | $475.00 | 11/07/2022 | Non-covered Recipient Entity DERMATOLOGY SPECIALISTS OF SPOKANE | A MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 24WEEK STUDY WITH A 28WEEK OPENLABEL EXTENSION TO ASSESS THE SAFETY AND EFFICACY OF ETRASIMOD IN SUBJECTS WITH MODERATETOSEVERE ALOPECIA AREATA | No dispute reported | 06/30/2026 | 949763429 |
| Principal investigator 1 | ARENA PHARMACEUTICALS, INC. | $9,190.63 | 11/07/2022 | Non-covered Recipient Entity DERMATOLOGY SPECIALISTS OF SPOKANE | A MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 24WEEK STUDY WITH A 28WEEK OPENLABEL EXTENSION TO ASSESS THE SAFETY AND EFFICACY OF ETRASIMOD IN SUBJECTS WITH MODERATETOSEVERE ALOPECIA AREATA | No dispute reported | 06/30/2026 | 949763487 |
| Principal investigator 1 | ARENA PHARMACEUTICALS, INC. | $5,792.00 | 11/07/2022 | Non-covered Recipient Entity DERMATOLOGY SPECIALISTS OF SPOKANE | A MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 24WEEK STUDY WITH A 28WEEK OPENLABEL EXTENSION TO ASSESS THE SAFETY AND EFFICACY OF ETRASIMOD IN SUBJECTS WITH MODERATETOSEVERE ALOPECIA AREATA | No dispute reported | 06/30/2026 | 949763491 |
| Principal investigator 1 | ARENA PHARMACEUTICALS, INC. | $2,677.50 | 11/07/2022 | Non-covered Recipient Entity DERMATOLOGY SPECIALISTS OF SPOKANE | A MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 24WEEK STUDY WITH A 28WEEK OPENLABEL EXTENSION TO ASSESS THE SAFETY AND EFFICACY OF ETRASIMOD IN SUBJECTS WITH MODERATETOSEVERE ALOPECIA AREATA | No dispute reported | 06/30/2026 | 949764983 |
| Principal investigator 1 | ARENA PHARMACEUTICALS, INC. | $1,232.50 | 11/07/2022 | Non-covered Recipient Entity DERMATOLOGY SPECIALISTS OF SPOKANE | A MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 24WEEK STUDY WITH A 28WEEK OPENLABEL EXTENSION TO ASSESS THE SAFETY AND EFFICACY OF ETRASIMOD IN SUBJECTS WITH MODERATETOSEVERE ALOPECIA AREATA | No dispute reported | 06/30/2026 | 949765085 |
| Principal investigator 1 | ARENA PHARMACEUTICALS, INC. | $2,677.50 | 11/07/2022 | Non-covered Recipient Entity DERMATOLOGY SPECIALISTS OF SPOKANE | A MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 24WEEK STUDY WITH A 28WEEK OPENLABEL EXTENSION TO ASSESS THE SAFETY AND EFFICACY OF ETRASIMOD IN SUBJECTS WITH MODERATETOSEVERE ALOPECIA AREATA | No dispute reported | 06/30/2026 | 949765141 |
| Principal investigator 1 | ARENA PHARMACEUTICALS, INC. | $1,232.50 | 11/07/2022 | Non-covered Recipient Entity DERMATOLOGY SPECIALISTS OF SPOKANE | A MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 24WEEK STUDY WITH A 28WEEK OPENLABEL EXTENSION TO ASSESS THE SAFETY AND EFFICACY OF ETRASIMOD IN SUBJECTS WITH MODERATETOSEVERE ALOPECIA AREATA | No dispute reported | 06/30/2026 | 949765243 |
| Principal investigator 1 | ARENA PHARMACEUTICALS, INC. | $1,370.63 | 11/07/2022 | Non-covered Recipient Entity DERMATOLOGY SPECIALISTS OF SPOKANE | A MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 24WEEK STUDY WITH A 28WEEK OPENLABEL EXTENSION TO ASSESS THE SAFETY AND EFFICACY OF ETRASIMOD IN SUBJECTS WITH MODERATETOSEVERE ALOPECIA AREATA | No dispute reported | 06/30/2026 | 949765503 |
| Principal investigator 1 | Incyte Corporation | $4,381.16 | 11/03/2022 | Non-covered Recipient Entity DERMATOLOGY SPECIALISTS OF SPOKANE | A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Children (Ages 2 Years to 12 Years) With Atopic Dermatitis (TRuE-AD3) | No dispute reported | 06/30/2026 | 905238619 |
| Principal investigator 1 | Incyte Corporation | $5,267.58 | 11/03/2022 | Non-covered Recipient Entity DERMATOLOGY SPECIALISTS OF SPOKANE | A Randomized, Double-Blind, Vehicle-Controlled Study to Evaluate the Mechanism of Action of Ruxolitinib Cream for Vitiligo | No dispute reported | 06/30/2026 | 905238621 |
| Principal investigator 1 | ABBVIE INC. | $3,935.60 | 10/14/2022 | Non-covered Recipient Entity DERMATOLOGY SPECIALISTS OF SPOKANE | A Study to Assess Adverse Events and Disease Activity With Cedirogant (ABBV-157) in Adult Participants With Moderate to Severe Psoriasis | No dispute reported | 06/30/2026 | 889816567 |
| Principal investigator 1 | ARENA PHARMACEUTICALS, INC. | $2,745.50 | 10/11/2022 | Non-covered Recipient Entity DERMATOLOGY SPECIALISTS OF SPOKANE | A MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 24WEEK STUDY WITH A 28WEEK OPENLABEL EXTENSION TO ASSESS THE SAFETY AND EFFICACY OF ETRASIMOD IN SUBJECTS WITH MODERATETOSEVERE ALOPECIA AREATA | No dispute reported | 06/30/2026 | 949763489 |
| Principal investigator 1 | ARENA PHARMACEUTICALS, INC. | $374.00 | 10/11/2022 | Non-covered Recipient Entity DERMATOLOGY SPECIALISTS OF SPOKANE | A MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 24WEEK STUDY WITH A 28WEEK OPENLABEL EXTENSION TO ASSESS THE SAFETY AND EFFICACY OF ETRASIMOD IN SUBJECTS WITH MODERATETOSEVERE ALOPECIA AREATA | No dispute reported | 06/30/2026 | 949765255 |
| Principal investigator 1 | ARENA PHARMACEUTICALS, INC. | $998.75 | 10/11/2022 | Non-covered Recipient Entity DERMATOLOGY SPECIALISTS OF SPOKANE | A MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 24WEEK STUDY WITH A 28WEEK OPENLABEL EXTENSION TO ASSESS THE SAFETY AND EFFICACY OF ETRASIMOD IN SUBJECTS WITH MODERATETOSEVERE ALOPECIA AREATA | No dispute reported | 06/30/2026 | 949765351 |
| Principal investigator 1 | ARENA PHARMACEUTICALS, INC. | $374.00 | 10/11/2022 | Non-covered Recipient Entity DERMATOLOGY SPECIALISTS OF SPOKANE | A MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 24WEEK STUDY WITH A 28WEEK OPENLABEL EXTENSION TO ASSESS THE SAFETY AND EFFICACY OF ETRASIMOD IN SUBJECTS WITH MODERATETOSEVERE ALOPECIA AREATA | No dispute reported | 06/30/2026 | 949765403 |
| Principal investigator 1 | ARENA PHARMACEUTICALS, INC. | $998.75 | 10/11/2022 | Non-covered Recipient Entity DERMATOLOGY SPECIALISTS OF SPOKANE | A MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 24WEEK STUDY WITH A 28WEEK OPENLABEL EXTENSION TO ASSESS THE SAFETY AND EFFICACY OF ETRASIMOD IN SUBJECTS WITH MODERATETOSEVERE ALOPECIA AREATA | No dispute reported | 06/30/2026 | 949765453 |
| Principal investigator 1 | Almirall LLC | $2,757.84 | 10/11/2022 | Non-covered Recipient Entity DERMATOLOGY SPECIALISTS OF SPOKANE | M14867-32 | No dispute reported | 06/30/2026 | 902933293 |
| Principal investigator 1 | Incyte Corporation | $4,041.98 | 10/05/2022 | Non-covered Recipient Entity DERMATOLOGY SPECIALISTS OF SPOKANE | A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Children (Ages 2 Years to 12 Years) With Atopic Dermatitis (TRuE-AD3) | No dispute reported | 06/30/2026 | 905238615 |
| Principal investigator 1 | ARENA PHARMACEUTICALS, INC. | $12,395.00 | 10/03/2022 | Non-covered Recipient Entity DERMATOLOGY SPECIALISTS OF SPOKANE | A MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 24WEEK STUDY WITH A 28WEEK OPENLABEL EXTENSION TO ASSESS THE SAFETY AND EFFICACY OF ETRASIMOD IN SUBJECTS WITH MODERATETOSEVERE ALOPECIA AREATA | No dispute reported | 06/30/2026 | 949763619 |
| Principal investigator 1 | Incyte Corporation | $1,200.00 | 09/22/2022 | Non-covered Recipient Entity DERMATOLOGY SPECIALISTS OF SPOKANE | A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 Followed by an Extension Period in Participants With Vitiligo | No dispute reported | 06/30/2026 | 905238561 |
| Principal investigator 1 | ARENA PHARMACEUTICALS, INC. | $950.94 | 09/12/2022 | Non-covered Recipient Entity DERMATOLOGY SPECIALISTS OF SPOKANE | A MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 24WEEK STUDY WITH A 28WEEK OPENLABEL EXTENSION TO ASSESS THE SAFETY AND EFFICACY OF ETRASIMOD IN SUBJECTS WITH MODERATETOSEVERE ALOPECIA AREATA | No dispute reported | 06/30/2026 | 949764937 |
| Principal investigator 1 | ARENA PHARMACEUTICALS, INC. | $2,677.50 | 09/12/2022 | Non-covered Recipient Entity DERMATOLOGY SPECIALISTS OF SPOKANE | A MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 24WEEK STUDY WITH A 28WEEK OPENLABEL EXTENSION TO ASSESS THE SAFETY AND EFFICACY OF ETRASIMOD IN SUBJECTS WITH MODERATETOSEVERE ALOPECIA AREATA | No dispute reported | 06/30/2026 | 949765295 |
| Principal investigator 1 | ARENA PHARMACEUTICALS, INC. | $950.94 | 09/12/2022 | Non-covered Recipient Entity DERMATOLOGY SPECIALISTS OF SPOKANE | A MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 24WEEK STUDY WITH A 28WEEK OPENLABEL EXTENSION TO ASSESS THE SAFETY AND EFFICACY OF ETRASIMOD IN SUBJECTS WITH MODERATETOSEVERE ALOPECIA AREATA | No dispute reported | 06/30/2026 | 949765413 |
| Principal investigator 1 | ARENA PHARMACEUTICALS, INC. | $1,232.50 | 09/12/2022 | Non-covered Recipient Entity DERMATOLOGY SPECIALISTS OF SPOKANE | A MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 24WEEK STUDY WITH A 28WEEK OPENLABEL EXTENSION TO ASSESS THE SAFETY AND EFFICACY OF ETRASIMOD IN SUBJECTS WITH MODERATETOSEVERE ALOPECIA AREATA | No dispute reported | 06/30/2026 | 949765499 |
| Principal investigator 1 | ARENA PHARMACEUTICALS, INC. | $950.94 | 09/12/2022 | Non-covered Recipient Entity DERMATOLOGY SPECIALISTS OF SPOKANE | A MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 24WEEK STUDY WITH A 28WEEK OPENLABEL EXTENSION TO ASSESS THE SAFETY AND EFFICACY OF ETRASIMOD IN SUBJECTS WITH MODERATETOSEVERE ALOPECIA AREATA | No dispute reported | 06/30/2026 | 949766449 |
| Principal investigator 1 | ARENA PHARMACEUTICALS, INC. | $374.00 | 09/12/2022 | Non-covered Recipient Entity DERMATOLOGY SPECIALISTS OF SPOKANE | A MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 24WEEK STUDY WITH A 28WEEK OPENLABEL EXTENSION TO ASSESS THE SAFETY AND EFFICACY OF ETRASIMOD IN SUBJECTS WITH MODERATETOSEVERE ALOPECIA AREATA | No dispute reported | 06/30/2026 | 949766453 |
| Principal investigator 1 | Almirall LLC | $4,079.16 | 09/12/2022 | Non-covered Recipient Entity DERMATOLOGY SPECIALISTS OF SPOKANE | M14867-32 | No dispute reported | 06/30/2026 | 902933231 |
| Principal investigator 1 | Almirall LLC | $1,100.00 | 09/12/2022 | Non-covered Recipient Entity DERMATOLOGY SPECIALISTS OF SPOKANE | M14867-32 | No dispute reported | 06/30/2026 | 902933233 |
| Principal investigator 1 | Incyte Corporation | $630.00 | 09/08/2022 | Non-covered Recipient Entity DERMATOLOGY SPECIALISTS OF SPOKANE | A Randomized, Double-Blind, Vehicle-Controlled Study to Evaluate the Mechanism of Action of Ruxolitinib Cream for Vitiligo | No dispute reported | 06/30/2026 | 905238553 |
| Principal investigator 1 | Kiniksa Pharmaceuticals, Ltd. | $5,250.00 | 09/07/2022 | Non-covered Recipient Entity Dermatology Specialist of Spokane | A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis | No dispute reported | 06/30/2026 | 949998151 |
| Principal investigator 1 | Incyte Corporation | $855.00 | 09/02/2022 | Non-covered Recipient Entity DERMATOLOGY SPECIALISTS OF SPOKANE | A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Children (Ages 2 Years to 12 Years) With Atopic Dermatitis (TRuE-AD3) | No dispute reported | 06/30/2026 | 905238555 |
| Principal investigator 1 | Incyte Corporation | $8,786.70 | 09/02/2022 | Non-covered Recipient Entity DERMATOLOGY SPECIALISTS OF SPOKANE | A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 Followed by an Extension Period in Participants With Vitiligo | No dispute reported | 06/30/2026 | 905238557 |
| Principal investigator 1 | Incyte Corporation | $1,080.00 | 09/02/2022 | Non-covered Recipient Entity DERMATOLOGY SPECIALISTS OF SPOKANE | A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 Followed by an Extension Period in Participants With Vitiligo | No dispute reported | 06/30/2026 | 905238559 |
| Principal investigator 1 | Incyte Corporation | $717.25 | 09/02/2022 | Non-covered Recipient Entity DERMATOLOGY SPECIALISTS OF SPOKANE | A Safety and Efficacy Study of Ruxolitinib Cream Combined With Narrow-Band Ultraviolet B Phototherapy in Participants With Vitiligo | No dispute reported | 06/30/2026 | 905238563 |
| Principal investigator 1 | Incyte Corporation | $1,458.99 | 08/26/2022 | Non-covered Recipient Entity DERMATOLOGY SPECIALISTS OF SPOKANE | A Randomized, Double-Blind, Vehicle-Controlled Study to Evaluate the Mechanism of Action of Ruxolitinib Cream for Vitiligo | No dispute reported | 06/30/2026 | 905238545 |
| Principal investigator 1 | Incyte Corporation | $13,767.02 | 08/26/2022 | Non-covered Recipient Entity DERMATOLOGY SPECIALISTS OF SPOKANE | A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Children (Ages 2 Years to 12 Years) With Atopic Dermatitis (TRuE-AD3) | No dispute reported | 06/30/2026 | 905238549 |
| Principal investigator 1 | Incyte Corporation | $181.00 | 08/26/2022 | Non-covered Recipient Entity DERMATOLOGY SPECIALISTS OF SPOKANE | A Safety and Efficacy Study of Ruxolitinib Cream Combined With Narrow-Band Ultraviolet B Phototherapy in Participants With Vitiligo | No dispute reported | 06/30/2026 | 905238551 |
| Principal investigator 1 | Kiniksa Pharmaceuticals, Ltd. | $300.00 | 08/24/2022 | Non-covered Recipient Entity Dermatology Specialist of Spokane | A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis | No dispute reported | 06/30/2026 | 949998153 |
| Principal investigator 1 | Kiniksa Pharmaceuticals, Ltd. | $1,650.00 | 08/24/2022 | Non-covered Recipient Entity Dermatology Specialist of Spokane | A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis | No dispute reported | 06/30/2026 | 949998155 |
| Principal investigator 1 | Kiniksa Pharmaceuticals, Ltd. | $140.68 | 08/12/2022 | Non-covered Recipient Entity Dermatology Specialist of Spokane | A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis | No dispute reported | 06/30/2026 | 949998145 |
| Principal investigator 1 | Kiniksa Pharmaceuticals, Ltd. | $217.62 | 08/12/2022 | Non-covered Recipient Entity Dermatology Specialist of Spokane | A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis | No dispute reported | 06/30/2026 | 949998147 |
| Principal investigator 1 | Kiniksa Pharmaceuticals, Ltd. | $300.00 | 08/12/2022 | Non-covered Recipient Entity Dermatology Specialist of Spokane | A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis | No dispute reported | 06/30/2026 | 949998169 |
| Principal investigator 1 | Kiniksa Pharmaceuticals, Ltd. | $1,650.00 | 08/12/2022 | Non-covered Recipient Entity Dermatology Specialist of Spokane | A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis | No dispute reported | 06/30/2026 | 949998171 |
| Principal investigator 1 | ARENA PHARMACEUTICALS, INC. | $1,317.50 | 08/09/2022 | Non-covered Recipient Entity DERMATOLOGY SPECIALISTS OF SPOKANE | A MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 24WEEK STUDY WITH A 28WEEK OPENLABEL EXTENSION TO ASSESS THE SAFETY AND EFFICACY OF ETRASIMOD IN SUBJECTS WITH MODERATETOSEVERE ALOPECIA AREATA | No dispute reported | 06/30/2026 | 949765083 |
| Principal investigator 1 | ARENA PHARMACEUTICALS, INC. | $374.00 | 08/09/2022 | Non-covered Recipient Entity DERMATOLOGY SPECIALISTS OF SPOKANE | A MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 24WEEK STUDY WITH A 28WEEK OPENLABEL EXTENSION TO ASSESS THE SAFETY AND EFFICACY OF ETRASIMOD IN SUBJECTS WITH MODERATETOSEVERE ALOPECIA AREATA | No dispute reported | 06/30/2026 | 949765143 |
| Principal investigator 1 | ARENA PHARMACEUTICALS, INC. | $1,700.00 | 08/09/2022 | Non-covered Recipient Entity DERMATOLOGY SPECIALISTS OF SPOKANE | A MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 24WEEK STUDY WITH A 28WEEK OPENLABEL EXTENSION TO ASSESS THE SAFETY AND EFFICACY OF ETRASIMOD IN SUBJECTS WITH MODERATETOSEVERE ALOPECIA AREATA | No dispute reported | 06/30/2026 | 949765193 |
| Principal investigator 1 | ARENA PHARMACEUTICALS, INC. | $536.56 | 08/09/2022 | Non-covered Recipient Entity DERMATOLOGY SPECIALISTS OF SPOKANE | A MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 24WEEK STUDY WITH A 28WEEK OPENLABEL EXTENSION TO ASSESS THE SAFETY AND EFFICACY OF ETRASIMOD IN SUBJECTS WITH MODERATETOSEVERE ALOPECIA AREATA | No dispute reported | 06/30/2026 | 949765197 |
| Principal investigator 1 | ARENA PHARMACEUTICALS, INC. | $1,700.00 | 08/09/2022 | Non-covered Recipient Entity DERMATOLOGY SPECIALISTS OF SPOKANE | A MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 24WEEK STUDY WITH A 28WEEK OPENLABEL EXTENSION TO ASSESS THE SAFETY AND EFFICACY OF ETRASIMOD IN SUBJECTS WITH MODERATETOSEVERE ALOPECIA AREATA | No dispute reported | 06/30/2026 | 949765553 |
| Principal investigator 1 | Almirall LLC | $6,000.00 | 08/09/2022 | Non-covered Recipient Entity DERMATOLOGY SPECIALISTS OF SPOKANE | M14867-32 | No dispute reported | 06/30/2026 | 902933167 |
| Principal investigator 1 | Incyte Corporation | $1,117.66 | 08/02/2022 | Non-covered Recipient Entity DERMATOLOGY SPECIALISTS OF SPOKANE | A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Children (Ages 2 Years to 12 Years) With Atopic Dermatitis (TRuE-AD3) | No dispute reported | 06/30/2026 | 905238547 |
| Principal investigator 1 | ARENA PHARMACEUTICALS, INC. | $950.94 | 06/30/2022 | Non-covered Recipient Entity DERMATOLOGY SPECIALISTS OF SPOKANE | A MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 24WEEK STUDY WITH A 28WEEK OPENLABEL EXTENSION TO ASSESS THE SAFETY AND EFFICACY OF ETRASIMOD IN SUBJECTS WITH MODERATETOSEVERE ALOPECIA AREATA | No dispute reported | 06/30/2026 | 949765207 |
| Principal investigator 1 | ARENA PHARMACEUTICALS, INC. | $536.56 | 06/30/2022 | Non-covered Recipient Entity DERMATOLOGY SPECIALISTS OF SPOKANE | A MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 24WEEK STUDY WITH A 28WEEK OPENLABEL EXTENSION TO ASSESS THE SAFETY AND EFFICACY OF ETRASIMOD IN SUBJECTS WITH MODERATETOSEVERE ALOPECIA AREATA | No dispute reported | 06/30/2026 | 949765247 |
| Principal investigator 1 | ARENA PHARMACEUTICALS, INC. | $675.00 | 06/30/2022 | Non-covered Recipient Entity DERMATOLOGY SPECIALISTS OF SPOKANE | A MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 24WEEK STUDY WITH A 28WEEK OPENLABEL EXTENSION TO ASSESS THE SAFETY AND EFFICACY OF ETRASIMOD IN SUBJECTS WITH MODERATETOSEVERE ALOPECIA AREATA | No dispute reported | 06/30/2026 | 949765399 |
| Principal investigator 1 | ARENA PHARMACEUTICALS, INC. | $1,317.50 | 06/30/2022 | Non-covered Recipient Entity DERMATOLOGY SPECIALISTS OF SPOKANE | A MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 24WEEK STUDY WITH A 28WEEK OPENLABEL EXTENSION TO ASSESS THE SAFETY AND EFFICACY OF ETRASIMOD IN SUBJECTS WITH MODERATETOSEVERE ALOPECIA AREATA | No dispute reported | 06/30/2026 | 949765411 |
| Principal investigator 1 | ARENA PHARMACEUTICALS, INC. | $950.94 | 06/30/2022 | Non-covered Recipient Entity DERMATOLOGY SPECIALISTS OF SPOKANE | A MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 24WEEK STUDY WITH A 28WEEK OPENLABEL EXTENSION TO ASSESS THE SAFETY AND EFFICACY OF ETRASIMOD IN SUBJECTS WITH MODERATETOSEVERE ALOPECIA AREATA | No dispute reported | 06/30/2026 | 949765451 |
| Principal investigator 1 | ARENA PHARMACEUTICALS, INC. | $200.00 | 06/30/2022 | Non-covered Recipient Entity DERMATOLOGY SPECIALISTS OF SPOKANE | A MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 24WEEK STUDY WITH A 28WEEK OPENLABEL EXTENSION TO ASSESS THE SAFETY AND EFFICACY OF ETRASIMOD IN SUBJECTS WITH MODERATETOSEVERE ALOPECIA AREATA | No dispute reported | 06/30/2026 | 949765455 |
| Principal investigator 1 | ARENA PHARMACEUTICALS, INC. | $950.94 | 06/30/2022 | Non-covered Recipient Entity DERMATOLOGY SPECIALISTS OF SPOKANE | A MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 24WEEK STUDY WITH A 28WEEK OPENLABEL EXTENSION TO ASSESS THE SAFETY AND EFFICACY OF ETRASIMOD IN SUBJECTS WITH MODERATETOSEVERE ALOPECIA AREATA | No dispute reported | 06/30/2026 | 949765501 |
| Principal investigator 1 | ARENA PHARMACEUTICALS, INC. | $998.75 | 06/30/2022 | Non-covered Recipient Entity DERMATOLOGY SPECIALISTS OF SPOKANE | A MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 24WEEK STUDY WITH A 28WEEK OPENLABEL EXTENSION TO ASSESS THE SAFETY AND EFFICACY OF ETRASIMOD IN SUBJECTS WITH MODERATETOSEVERE ALOPECIA AREATA | No dispute reported | 06/30/2026 | 949765551 |
| Principal investigator 1 | Incyte Corporation | $1,159.47 | 06/24/2022 | Non-covered Recipient Entity DERMATOLOGY SPECIALISTS OF SPOKANE | A Randomized, Double-Blind, Vehicle-Controlled Study to Evaluate the Mechanism of Action of Ruxolitinib Cream for Vitiligo | No dispute reported | 06/30/2026 | 905238539 |
| Principal investigator 1 | Incyte Corporation | $1,998.79 | 06/24/2022 | Non-covered Recipient Entity DERMATOLOGY SPECIALISTS OF SPOKANE | A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Children (Ages 2 Years to 12 Years) With Atopic Dermatitis (TRuE-AD3) | No dispute reported | 06/30/2026 | 905238543 |
| Principal investigator 1 | ABBVIE INC. | $3,000.00 | 06/23/2022 | Non-covered Recipient Entity DERMATOLOGY SPECIALISTS OF SPOKANE | A Study of Oral Upadacitinib Tablet Compared to Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa to Assess Change in Disease Symptoms | No dispute reported | 06/30/2026 | 889796911 |
| Principal investigator 1 | ABBVIE INC. | $408.00 | 06/23/2022 | Non-covered Recipient Entity DERMATOLOGY SPECIALISTS OF SPOKANE | A Study of Oral Upadacitinib Tablet Compared to Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa to Assess Change in Disease Symptoms | No dispute reported | 06/30/2026 | 889797059 |
| Principal investigator 1 | Kiniksa Pharmaceuticals, Ltd. | $3,672.00 | 06/17/2022 | Non-covered Recipient Entity Dermatology Specialist of Spokane | A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis | No dispute reported | 06/30/2026 | 949998129 |
| Principal investigator 1 | Kiniksa Pharmaceuticals, Ltd. | $2,561.62 | 06/17/2022 | Non-covered Recipient Entity Dermatology Specialist of Spokane | A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis | No dispute reported | 06/30/2026 | 949998131 |
| Principal investigator 1 | Kiniksa Pharmaceuticals, Ltd. | $568.75 | 06/13/2022 | Non-covered Recipient Entity Dermatology Specialist of Spokane | A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis | No dispute reported | 06/30/2026 | 949998125 |
| Principal investigator 1 | Kiniksa Pharmaceuticals, Ltd. | $1,708.75 | 06/13/2022 | Non-covered Recipient Entity Dermatology Specialist of Spokane | A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis | No dispute reported | 06/30/2026 | 949998127 |
| Principal investigator 1 | Kiniksa Pharmaceuticals, Ltd. | $568.75 | 06/13/2022 | Non-covered Recipient Entity Dermatology Specialist of Spokane | A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis | No dispute reported | 06/30/2026 | 949998185 |
| Principal investigator 1 | Incyte Corporation | $1,000.00 | 06/10/2022 | Non-covered Recipient Entity DERMATOLOGY SPECIALISTS OF SPOKANE | A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Children (Ages 2 Years to 12 Years) With Atopic Dermatitis (TRuE-AD3) | No dispute reported | 06/30/2026 | 905238541 |
| Principal investigator 1 | ARENA PHARMACEUTICALS, INC. | $903.13 | 06/07/2022 | Non-covered Recipient Entity DERMATOLOGY SPECIALISTS OF SPOKANE | A MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 24WEEK STUDY WITH A 28WEEK OPENLABEL EXTENSION TO ASSESS THE SAFETY AND EFFICACY OF ETRASIMOD IN SUBJECTS WITH MODERATETOSEVERE ALOPECIA AREATA | No dispute reported | 06/30/2026 | 949764939 |
| Principal investigator 1 | ARENA PHARMACEUTICALS, INC. | $1,184.69 | 06/07/2022 | Non-covered Recipient Entity DERMATOLOGY SPECIALISTS OF SPOKANE | A MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 24WEEK STUDY WITH A 28WEEK OPENLABEL EXTENSION TO ASSESS THE SAFETY AND EFFICACY OF ETRASIMOD IN SUBJECTS WITH MODERATETOSEVERE ALOPECIA AREATA | No dispute reported | 06/30/2026 | 949764941 |
| Principal investigator 1 | ARENA PHARMACEUTICALS, INC. | $4,547.50 | 06/07/2022 | Non-covered Recipient Entity DERMATOLOGY SPECIALISTS OF SPOKANE | A MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 24WEEK STUDY WITH A 28WEEK OPENLABEL EXTENSION TO ASSESS THE SAFETY AND EFFICACY OF ETRASIMOD IN SUBJECTS WITH MODERATETOSEVERE ALOPECIA AREATA | No dispute reported | 06/30/2026 | 949765205 |
| Principal investigator 1 | ARENA PHARMACEUTICALS, INC. | $536.56 | 06/07/2022 | Non-covered Recipient Entity DERMATOLOGY SPECIALISTS OF SPOKANE | A MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 24WEEK STUDY WITH A 28WEEK OPENLABEL EXTENSION TO ASSESS THE SAFETY AND EFFICACY OF ETRASIMOD IN SUBJECTS WITH MODERATETOSEVERE ALOPECIA AREATA | No dispute reported | 06/30/2026 | 949765209 |
| Principal investigator 1 | ARENA PHARMACEUTICALS, INC. | $536.56 | 06/07/2022 | Non-covered Recipient Entity DERMATOLOGY SPECIALISTS OF SPOKANE | A MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 24WEEK STUDY WITH A 28WEEK OPENLABEL EXTENSION TO ASSESS THE SAFETY AND EFFICACY OF ETRASIMOD IN SUBJECTS WITH MODERATETOSEVERE ALOPECIA AREATA | No dispute reported | 06/30/2026 | 949765245 |
| Principal investigator 1 | ARENA PHARMACEUTICALS, INC. | $950.94 | 06/07/2022 | Non-covered Recipient Entity DERMATOLOGY SPECIALISTS OF SPOKANE | A MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 24WEEK STUDY WITH A 28WEEK OPENLABEL EXTENSION TO ASSESS THE SAFETY AND EFFICACY OF ETRASIMOD IN SUBJECTS WITH MODERATETOSEVERE ALOPECIA AREATA | No dispute reported | 06/30/2026 | 949765257 |
| Principal investigator 1 | ARENA PHARMACEUTICALS, INC. | $1,673.44 | 06/07/2022 | Non-covered Recipient Entity DERMATOLOGY SPECIALISTS OF SPOKANE | A MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 24WEEK STUDY WITH A 28WEEK OPENLABEL EXTENSION TO ASSESS THE SAFETY AND EFFICACY OF ETRASIMOD IN SUBJECTS WITH MODERATETOSEVERE ALOPECIA AREATA | No dispute reported | 06/30/2026 | 949765291 |
| Principal investigator 1 | ARENA PHARMACEUTICALS, INC. | $1,673.44 | 06/07/2022 | Non-covered Recipient Entity DERMATOLOGY SPECIALISTS OF SPOKANE | A MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 24WEEK STUDY WITH A 28WEEK OPENLABEL EXTENSION TO ASSESS THE SAFETY AND EFFICACY OF ETRASIMOD IN SUBJECTS WITH MODERATETOSEVERE ALOPECIA AREATA | No dispute reported | 06/30/2026 | 949765293 |
| Principal investigator 1 | ARENA PHARMACEUTICALS, INC. | $1,184.69 | 06/07/2022 | Non-covered Recipient Entity DERMATOLOGY SPECIALISTS OF SPOKANE | A MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 24WEEK STUDY WITH A 28WEEK OPENLABEL EXTENSION TO ASSESS THE SAFETY AND EFFICACY OF ETRASIMOD IN SUBJECTS WITH MODERATETOSEVERE ALOPECIA AREATA | No dispute reported | 06/30/2026 | 949765347 |
| Principal investigator 1 | ARENA PHARMACEUTICALS, INC. | $4,547.50 | 06/07/2022 | Non-covered Recipient Entity DERMATOLOGY SPECIALISTS OF SPOKANE | A MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 24WEEK STUDY WITH A 28WEEK OPENLABEL EXTENSION TO ASSESS THE SAFETY AND EFFICACY OF ETRASIMOD IN SUBJECTS WITH MODERATETOSEVERE ALOPECIA AREATA | No dispute reported | 06/30/2026 | 949765349 |
| Principal investigator 1 | ARENA PHARMACEUTICALS, INC. | $1,317.50 | 06/07/2022 | Non-covered Recipient Entity DERMATOLOGY SPECIALISTS OF SPOKANE | A MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 24WEEK STUDY WITH A 28WEEK OPENLABEL EXTENSION TO ASSESS THE SAFETY AND EFFICACY OF ETRASIMOD IN SUBJECTS WITH MODERATETOSEVERE ALOPECIA AREATA | No dispute reported | 06/30/2026 | 949765401 |
| Principal investigator 1 | ARENA PHARMACEUTICALS, INC. | $950.94 | 06/07/2022 | Non-covered Recipient Entity DERMATOLOGY SPECIALISTS OF SPOKANE | A MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 24WEEK STUDY WITH A 28WEEK OPENLABEL EXTENSION TO ASSESS THE SAFETY AND EFFICACY OF ETRASIMOD IN SUBJECTS WITH MODERATETOSEVERE ALOPECIA AREATA | No dispute reported | 06/30/2026 | 949765415 |
| Principal investigator 1 | ARENA PHARMACEUTICALS, INC. | $1,700.00 | 06/07/2022 | Non-covered Recipient Entity DERMATOLOGY SPECIALISTS OF SPOKANE | A MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 24WEEK STUDY WITH A 28WEEK OPENLABEL EXTENSION TO ASSESS THE SAFETY AND EFFICACY OF ETRASIMOD IN SUBJECTS WITH MODERATETOSEVERE ALOPECIA AREATA | No dispute reported | 06/30/2026 | 949765555 |
| Principal investigator 1 | ARENA PHARMACEUTICALS, INC. | $903.13 | 06/07/2022 | Non-covered Recipient Entity DERMATOLOGY SPECIALISTS OF SPOKANE | A MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 24WEEK STUDY WITH A 28WEEK OPENLABEL EXTENSION TO ASSESS THE SAFETY AND EFFICACY OF ETRASIMOD IN SUBJECTS WITH MODERATETOSEVERE ALOPECIA AREATA | No dispute reported | 06/30/2026 | 949766451 |
| Principal investigator 1 | Incyte Corporation | $4,064.85 | 05/31/2022 | Non-covered Recipient Entity DERMATOLOGY SPECIALISTS OF SPOKANE | A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Children (Ages 2 Years to 12 Years) With Atopic Dermatitis (TRuE-AD3) | No dispute reported | 06/30/2026 | 905238527 |
| Principal investigator 1 | Incyte Corporation | $3,355.56 | 05/31/2022 | Non-covered Recipient Entity DERMATOLOGY SPECIALISTS OF SPOKANE | A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 Followed by an Extension Period in Participants With Vitiligo | No dispute reported | 06/30/2026 | 905238537 |
| Principal investigator 1 | Incyte Corporation | $1,750.00 | 05/13/2022 | Non-covered Recipient Entity DERMATOLOGY SPECIALISTS OF SPOKANE | A Double-Blind, Vehicle-Controlled, Randomized Withdrawal and Treatment Extension Study to Assess the Long-Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo | No dispute reported | 06/30/2026 | 905238533 |
| Principal investigator 1 | ARENA PHARMACEUTICALS, INC. | $1,673.44 | 05/10/2022 | Non-covered Recipient Entity DERMATOLOGY SPECIALISTS OF SPOKANE | A MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 24WEEK STUDY WITH A 28WEEK OPENLABEL EXTENSION TO ASSESS THE SAFETY AND EFFICACY OF ETRASIMOD IN SUBJECTS WITH MODERATETOSEVERE ALOPECIA AREATA | No dispute reported | 06/30/2026 | 949765139 |
| Principal investigator 1 | ARENA PHARMACEUTICALS, INC. | $950.94 | 05/10/2022 | Non-covered Recipient Entity DERMATOLOGY SPECIALISTS OF SPOKANE | A MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 24WEEK STUDY WITH A 28WEEK OPENLABEL EXTENSION TO ASSESS THE SAFETY AND EFFICACY OF ETRASIMOD IN SUBJECTS WITH MODERATETOSEVERE ALOPECIA AREATA | No dispute reported | 06/30/2026 | 949765195 |
| Principal investigator 1 | Incyte Corporation | $1,298.00 | 05/06/2022 | Non-covered Recipient Entity DERMATOLOGY SPECIALISTS OF SPOKANE | A Double-Blind, Vehicle-Controlled, Randomized Withdrawal and Treatment Extension Study to Assess the Long-Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo | No dispute reported | 06/30/2026 | 905238531 |
| Principal investigator 1 | Incyte Corporation | $3,095.82 | 05/03/2022 | Non-covered Recipient Entity DERMATOLOGY SPECIALISTS OF SPOKANE | A Randomized, Double-Blind, Vehicle-Controlled Study to Evaluate the Mechanism of Action of Ruxolitinib Cream for Vitiligo | No dispute reported | 06/30/2026 | 905238523 |
| Principal investigator 1 | Incyte Corporation | $5,260.47 | 05/03/2022 | Non-covered Recipient Entity DERMATOLOGY SPECIALISTS OF SPOKANE | A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Children (Ages 2 Years to 12 Years) With Atopic Dermatitis (TRuE-AD3) | No dispute reported | 06/30/2026 | 905238525 |
| Principal investigator 1 | Incyte Corporation | $1,389.37 | 05/03/2022 | Non-covered Recipient Entity DERMATOLOGY SPECIALISTS OF SPOKANE | A Double-Blind, Vehicle-Controlled, Randomized Withdrawal and Treatment Extension Study to Assess the Long-Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo | No dispute reported | 06/30/2026 | 905238529 |
| Principal investigator 1 | Incyte Corporation | $5,212.35 | 05/03/2022 | Non-covered Recipient Entity DERMATOLOGY SPECIALISTS OF SPOKANE | A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 Followed by an Extension Period in Participants With Vitiligo | No dispute reported | 06/30/2026 | 905238535 |
| Principal investigator 1 | Kiniksa Pharmaceuticals, Ltd. | $5,395.50 | 04/26/2022 | Non-covered Recipient Entity Dermatology Specialist of Spokane | A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis | No dispute reported | 06/30/2026 | 949998123 |
| Principal investigator 1 | ABBVIE INC. | $1,612.75 | 04/21/2022 | Non-covered Recipient Entity DERMATOLOGY SPECIALISTS OF SPOKANE | A Study of Oral Upadacitinib Tablet Compared to Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa to Assess Change in Disease Symptoms | No dispute reported | 06/30/2026 | 889787915 |
| Principal investigator 1 | Incyte Corporation | $525.00 | 04/15/2022 | Non-covered Recipient Entity DERMATOLOGY SPECIALISTS OF SPOKANE | A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 Followed by an Extension Period in Participants With Vitiligo | No dispute reported | 06/30/2026 | 905238495 |
| Principal investigator 1 | ABBVIE INC. | $8,400.00 | 04/14/2022 | Non-covered Recipient Entity DERMATOLOGY SPECIALISTS OF SPOKANE | A Study to Assess Adverse Events and Disease Activity With Cedirogant (ABBV-157) in Adult Participants With Moderate to Severe Psoriasis | No dispute reported | 06/30/2026 | 889786177 |
| Principal investigator 1 | Kiniksa Pharmaceuticals, Ltd. | $20,682.00 | 04/14/2022 | Non-covered Recipient Entity Dermatology Specialist of Spokane | A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis | No dispute reported | 06/30/2026 | 949998121 |
| Principal investigator 1 | ARENA PHARMACEUTICALS, INC. | $740.00 | 04/05/2022 | Non-covered Recipient Entity DERMATOLOGY SPECIALISTS OF SPOKANE | A MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 24WEEK STUDY WITH A 28WEEK OPENLABEL EXTENSION TO ASSESS THE SAFETY AND EFFICACY OF ETRASIMOD IN SUBJECTS WITH MODERATETOSEVERE ALOPECIA AREATA | No dispute reported | 06/30/2026 | 949765259 |
| Principal investigator 1 | Kiniksa Pharmaceuticals, Ltd. | $12.89 | 04/05/2022 | Non-covered Recipient Entity Dermatology Specialist of Spokane | A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis | No dispute reported | 06/30/2026 | 949998119 |
| Principal investigator 1 | Incyte Corporation | $525.00 | 04/01/2022 | Non-covered Recipient Entity DERMATOLOGY SPECIALISTS OF SPOKANE | A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Children (Ages 2 Years to 12 Years) With Atopic Dermatitis (TRuE-AD3) | No dispute reported | 06/30/2026 | 905238493 |
| Principal investigator 1 | ARENA PHARMACEUTICALS, INC. | $4,440.00 | 03/29/2022 | Non-covered Recipient Entity DERMATOLOGY SPECIALISTS OF SPOKANE | A MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 24WEEK STUDY WITH A 28WEEK OPENLABEL EXTENSION TO ASSESS THE SAFETY AND EFFICACY OF ETRASIMOD IN SUBJECTS WITH MODERATETOSEVERE ALOPECIA AREATA | No dispute reported | 06/30/2026 | 949765087 |
| Principal investigator 1 | Incyte Corporation | $750.00 | 03/25/2022 | Non-covered Recipient Entity DERMATOLOGY SPECIALISTS OF SPOKANE | A Randomized, Double-Blind, Vehicle-Controlled Study to Evaluate the Mechanism of Action of Ruxolitinib Cream for Vitiligo | No dispute reported | 06/30/2026 | 905238511 |
| Principal investigator 1 | Incyte Corporation | $7,019.00 | 03/25/2022 | Non-covered Recipient Entity DERMATOLOGY SPECIALISTS OF SPOKANE | A Safety and Efficacy Study of Ruxolitinib Cream Combined With Narrow-Band Ultraviolet B Phototherapy in Participants With Vitiligo | No dispute reported | 06/30/2026 | 905238513 |
| Principal investigator 1 | Incyte Corporation | $4,641.74 | 03/25/2022 | Non-covered Recipient Entity DERMATOLOGY SPECIALISTS OF SPOKANE | A Double-Blind, Vehicle-Controlled, Randomized Withdrawal and Treatment Extension Study to Assess the Long-Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo | No dispute reported | 06/30/2026 | 905238515 |
| Principal investigator 1 | Incyte Corporation | $3,006.90 | 03/25/2022 | Non-covered Recipient Entity DERMATOLOGY SPECIALISTS OF SPOKANE | A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 Followed by an Extension Period in Participants With Vitiligo | No dispute reported | 06/30/2026 | 905238517 |
| Principal investigator 1 | Incyte Corporation | $30.95 | 03/04/2022 | Non-covered Recipient Entity DERMATOLOGY SPECIALISTS OF SPOKANE | A Randomized, Double-Blind, Vehicle-Controlled Study to Evaluate the Mechanism of Action of Ruxolitinib Cream for Vitiligo | No dispute reported | 06/30/2026 | 905238509 |
| Principal investigator 1 | Kiniksa Pharmaceuticals, Ltd. | $351.70 | 03/03/2022 | Non-covered Recipient Entity Dermatology Specialist of Spokane | A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis | No dispute reported | 06/30/2026 | 949998105 |
| Principal investigator 1 | Kiniksa Pharmaceuticals, Ltd. | $32.00 | 03/01/2022 | Non-covered Recipient Entity Dermatology Specialist of Spokane | A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis | No dispute reported | 06/30/2026 | 949998107 |
| Principal investigator 1 | Incyte Corporation | $3,777.93 | 02/25/2022 | Non-covered Recipient Entity DERMATOLOGY SPECIALISTS OF SPOKANE | A Randomized, Double-Blind, Vehicle-Controlled Study to Evaluate the Mechanism of Action of Ruxolitinib Cream for Vitiligo | No dispute reported | 06/30/2026 | 905238499 |
| Principal investigator 1 | Incyte Corporation | $5,218.80 | 02/25/2022 | Non-covered Recipient Entity DERMATOLOGY SPECIALISTS OF SPOKANE | A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Children (Ages 2 Years to 12 Years) With Atopic Dermatitis (TRuE-AD3) | No dispute reported | 06/30/2026 | 905238501 |
| Principal investigator 1 | Incyte Corporation | $450.00 | 02/25/2022 | Non-covered Recipient Entity DERMATOLOGY SPECIALISTS OF SPOKANE | Topical Ruxolitinib Evaluation in Vitiligo Study 1 (TRuE-V1)A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Extension Period in Participants With Vitiligo | No dispute reported | 06/30/2026 | 905238503 |
| Principal investigator 1 | Kiniksa Pharmaceuticals, Ltd. | $362.70 | 02/23/2022 | Non-covered Recipient Entity Dermatology Specialist of Spokane | A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis | No dispute reported | 06/30/2026 | 949998095 |
| Principal investigator 1 | Kiniksa Pharmaceuticals, Ltd. | $351.70 | 02/23/2022 | Non-covered Recipient Entity Dermatology Specialist of Spokane | A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis | No dispute reported | 06/30/2026 | 949998097 |
| Principal investigator 1 | Kiniksa Pharmaceuticals, Ltd. | $247.30 | 02/23/2022 | Non-covered Recipient Entity Dermatology Specialist of Spokane | A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis | No dispute reported | 06/30/2026 | 949998099 |
| Principal investigator 1 | Kiniksa Pharmaceuticals, Ltd. | $197.84 | 02/23/2022 | Non-covered Recipient Entity Dermatology Specialist of Spokane | A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis | No dispute reported | 06/30/2026 | 949998101 |
| Principal investigator 1 | Kiniksa Pharmaceuticals, Ltd. | $108.88 | 02/23/2022 | Non-covered Recipient Entity Dermatology Specialist of Spokane | A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis | No dispute reported | 06/30/2026 | 949998103 |
| Principal investigator 1 | Kiniksa Pharmaceuticals, Ltd. | $8,370.00 | 02/10/2022 | Non-covered Recipient Entity Dermatology Specialist of Spokane | A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis | No dispute reported | 06/30/2026 | 949998111 |
| Principal investigator 1 | ABBVIE INC. | $1,699.25 | 02/08/2022 | Non-covered Recipient Entity DERMATOLOGY SPECIALISTS OF SPOKANE | A Study of Oral Upadacitinib Tablet Compared to Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa to Assess Change in Disease Symptoms | No dispute reported | 06/30/2026 | 889776253 |
| Principal investigator 1 | Kiniksa Pharmaceuticals, Ltd. | $2,145.37 | 02/01/2022 | Non-covered Recipient Entity Dermatology Specialist of Spokane | A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis | No dispute reported | 06/30/2026 | 949998109 |
| Principal investigator 1 | Incyte Corporation | $1,636.83 | 01/28/2022 | Non-covered Recipient Entity DERMATOLOGY SPECIALISTS OF SPOKANE | A Randomized, Double-Blind, Vehicle-Controlled Study to Evaluate the Mechanism of Action of Ruxolitinib Cream for Vitiligo | No dispute reported | 06/30/2026 | 905238483 |
| Principal investigator 1 | Incyte Corporation | $3,726.00 | 01/28/2022 | Non-covered Recipient Entity DERMATOLOGY SPECIALISTS OF SPOKANE | A Double-Blind, Vehicle-Controlled, Randomized Withdrawal and Treatment Extension Study to Assess the Long-Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo | No dispute reported | 06/30/2026 | 905238485 |
| Principal investigator 1 | Incyte Corporation | $4,336.02 | 01/28/2022 | Non-covered Recipient Entity DERMATOLOGY SPECIALISTS OF SPOKANE | A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 Followed by an Extension Period in Participants With Vitiligo | No dispute reported | 06/30/2026 | 905238487 |
| Principal investigator 1 | Incyte Corporation | $13,360.11 | 01/28/2022 | Non-covered Recipient Entity DERMATOLOGY SPECIALISTS OF SPOKANE | Topical Ruxolitinib Evaluation in Vitiligo Study 1 (TRuE-V1)A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Extension Period in Participants With Vitiligo | No dispute reported | 06/30/2026 | 905238489 |
| Principal investigator 1 | Kiniksa Pharmaceuticals, Ltd. | $44.98 | 01/21/2022 | Non-covered Recipient Entity Dermatology Specialist of Spokane | A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis | No dispute reported | 06/30/2026 | 949997905 |
| Principal investigator 1 | Kiniksa Pharmaceuticals, Ltd. | $49.46 | 01/21/2022 | Non-covered Recipient Entity Dermatology Specialist of Spokane | A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis | No dispute reported | 06/30/2026 | 949997907 |
| Principal investigator 1 | Kiniksa Pharmaceuticals, Ltd. | $6.25 | 01/21/2022 | Non-covered Recipient Entity Dermatology Specialist of Spokane | A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis | No dispute reported | 06/30/2026 | 949997909 |
| Principal investigator 1 | Kiniksa Pharmaceuticals, Ltd. | $38.40 | 01/21/2022 | Non-covered Recipient Entity Dermatology Specialist of Spokane | A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis | No dispute reported | 06/30/2026 | 949997911 |
| Principal investigator 1 | Incyte Corporation | $4,449.00 | 01/07/2022 | Non-covered Recipient Entity DERMATOLOGY SPECIALISTS OF SPOKANE | Topical Ruxolitinib Evaluation in Vitiligo Study 1 (TRuE-V1)A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Extension Period in Participants With Vitiligo | No dispute reported | 06/30/2026 | 905238481 |